Get started
Author

Xiaobin Yuan

Observed names: X Yuan, X. Yuan, Yuan Xiaobin, Yuan, Xiaobin
Observed institutions: University of Louisville, University of Shanghai for Science and Technology, Shanxi Medical University, Sir Run Run Shaw Hospital, Chinese PLA General Hospital, Bristol-Myers Squibb (United States), Peking University Cancer Hospital, Betta Pharmaceuticals (China), Zhuhai People's Hospital, Shanxi Province Hospital of Traditional Chinese Medicine, First Hospital of Shanxi Medical University, First Affiliated Hospital of Chinese PLA General Hospital, Eisai (United States), Shanxi Academy of Medical Sciences, Tongji Hospital, Chinese People's Liberation Army, Qingdao Haici Medical Group, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Huazhong University of Science and Technology, Zhejiang University
ORCID: 0000-0002-0497-430X
Observed ORCID: 0000-0002-0497-430X
OpenAlex ID: A5058684604
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
2021 · David P. Steensma, Martin Wermke, et al. · Leukemia · 189
PDF
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
2019 · Yunpeng Yang, Jianya Zhou, et al. · The Lancet Respiratory Medicine · 141
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
2019 · David P. Steensma, Martin Wermke, et al. · Blood · 88
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
2023 · Shun Lu, Jianying Zhou, et al. · The Lancet Respiratory Medicine · 77
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing
2021 · Yunpeng Yang, Jie Huang, et al. · Journal of Thoracic Oncology · 45
Intratumoral heterogeneity and genetic characteristics of prostate cancer
2020 · Bo Wu, Xin Lu, et al. · International Journal of Cancer · 43
PDF
Icotinib, a Selective EGF Receptor Tyrosine Kinase Inhibitor, for the Treatment of Non-Small-Cell Lung Cancer
2015 · Fenlai Tan, Yuankai Shi, et al. · Future Oncology · 41
Preoperative planning and real-time assisted navigation by three-dimensional individual digital model in partial nephrectomy with three-dimensional laparoscopic system
2015 · Dongwen Wang, Bin Zhang, et al. · International Journal of Computer Assisted Radiology and Surgery · 37
Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
2022 · Chris Liang, Xiaobin Yuan, et al. · Molecular Therapy — Oncolytics · 34
PDF
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
2022 · Shun Lu, Yiping Zhang, et al. · Journal of Thoracic Oncology · 27
PDF
Efficacy of Dasatinib in Patients with Accelerated-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-A (CA180-005).
2007 · Francois Guilhot, Jane F. Apperley, et al. · Blood · 24
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
2022 · Xinan Sheng, Dingwei Ye, et al. · European Journal of Cancer · 23
Studies on tabellae indigo naturalis in treatment of psoriasis.
1982 · Z Z Yuan, X Yuan, et al. · PubMed · 19
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study
2021 · Xinghao Ai, Qiming Wang, et al. · Journal of Thoracic Oncology · 16
PDF
Epidemiological trends of urolithiasis in working-age populations: Findings from the global burden of disease study 1990–2021
2025 · Weitao Yao, Xin Wei, et al. · PLoS ONE · 14
PDF
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
2021 · Rui Wan, Xiaorong Dong, et al. · EClinicalMedicine · 14
PDF
Confidence Intervals for Survival Probabilities: A Comparison Study
2011 · Xiaobin Yuan, Shesh N. Rai · Communications in Statistics - Simulation and Computation · 14
Endoplasmic reticulum stress is involved in apoptosis of detrusor muscle in streptozocin‐induced diabetic rats
2015 · Dongwen Wang, Dongwen Wang, et al. · Neurourology and Urodynamics · 13
Gut Microbiota and Their Metabolites: The Hidden Driver of Diabetic Nephropathy? Unveiling Gut Microbe's Role in DN
2025 · Jinzhou Liu, Min Guo, et al. · Journal of Diabetes · 11
PDF
Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study
2020 · Wen Zhang, Yiping Zhang, et al. · Journal of Thoracic Disease · 9
PDF
Clinicopathologica Epidemiological Characteristics and Change Tendencies of Renal Cell Carcinoma in Shanxi Province of China from 2005 to 2014
2015 · Tao Bai, Li Wang, et al. · PLoS ONE · 9
PDF
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
2023 · Xingsheng Hu, Xinge Cui, et al. · BMC Cancer · 8
PDF
Estimating Incidence Rate on Current Status Data with Application to a Phase IV Cancer Trial
2013 · Shesh N. Rai, Jianmin Pan, et al. · Communication in Statistics- Theory and Methods · 8
Abdominal wall component release is a sensible choice for patients requiring complicated closure of abdominal defects
2011 · Ziad Kanaan, Nathan Hicks, et al. · Langenbeck s Archives of Surgery · 8
Clinical comparative study of single-use and reusable digital flexible ureteroscopy for the treatment of lower pole stones: a retrospective case-controlled study
2024 · Qiang Jing, Fan Liu, et al. · BMC Urology · 6
PDF
Works count: 75
Citation count: 968
H-index: 14
I10-index: 19
Year
Topic
Type